Sort
15,273 grants matching “antimicrobial resistance”
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections
$471,414Laura Ensign · Johns Hopkins University · R01 · FY2023 · EY
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections
$471,413Laura Ensign · Johns Hopkins University · R01 · FY2025 · EY
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections
$471,413Laura Ensign · Johns Hopkins University · R01 · FY2024 · EY
Eye drop formulations for enhanced penetration of water soluble antibiotics to treat infections
$471,413Laura Ensign · Johns Hopkins University · R01 · FY2022 · EY
Role of bacterial aggregation and biofilms in gonococcal pathogenesis
$471,394Daniel C Stein · Univ Of Maryland, College Park · R01 · FY2019 · AI
Role of bacterial aggregation and biofilms in gonococcal pathogenesis
$471,394Daniel C Stein · Univ Of Maryland, College Park · R01 · FY2020 · AI
Staphylococcus aueaus vaccine development
$471,281Juliane Bubeck Wardenburg · University Of Chicago · U54 · FY2010 · AI
A Randomized Controlled Trial of a Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care
$471,279Larisa Grigoryan · Baylor College Of Medicine · R01 · FY2023 · HS
Precision coordination of therapeutic and prophylactic antibiotics to reduce infection, toxicity, and emergence of resistance following acute abdominal surgery
$471,078Manjunath P Pai · University Of Michigan At Ann Arbor · R01 · FY2023 · HS
Non-clinical Development of Bactericidal Proteins Targeting Plague
$470,775David William Martin · Avidbiotics Corporation · R44 · FY2010 · AI
Phenotype MicroArray Analysis of Fastidious Pathogens
$470,751Barry Ronald Bochner · Biolog, Inc. · R42 · FY2007 · GM
Targeted Clinical Trials To Reduce the Risk of Antimicrobial Resistance
$470,748Alehandro Hoberman · University Of Pittsburgh At Pittsburgh · N01 · FY2015 · AI
Trophoblast development and placental susceptibility to cytomegalovirus infection
$470,637Craig John Bierle · University Of Minnesota · R01 · FY2024 · HD
Deep Learning Based Pharmacokinetic Model for Vancomycin
$470,454Masayuki Nigo · Methodist Hospital Research Institute · R01 · FY2024 · AI
Decoding the microbial bioburden of diabetic foot ulcers: A metagenomic approach
$470,350Elizabeth Anne Grice · University Of Pennsylvania · R01 · FY2017 · NR
Phage resistance and mobile genetic elements in Vibrio cholerae
$470,343Kimberley Diane Seed · University Of California Berkeley · R01 · FY2019 · AI
Cell-mediated protection against pneumonic plague
$470,264Stephen T Smiley · Trudeau Institute, Inc. · R01 · FY2011 · AI
Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung Injury
$470,190Jae Woo Lee · University Of California, San Francisco · R01 · FY2019 · HL
Microbiome Function in Atopic Dermatitis
$470,159Richard L Gallo · University Of California, San Diego · U01 · FY2024 · AI
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy
$470,003Gunnar Joerg Floris Kaufmann · Scripps Research Institute, The · R01 · FY2010 · AI
Cell-mediated protection against pneumonic plague
$469,961Stephen T Smiley · Trudeau Institute, Inc. · R01 · FY2012 · AI
Understanding and Informing Early Hospital Antibiotic Prescribing for Potential Infection
$469,915Hallie Christine Prescott · University Of Michigan At Ann Arbor · R01 · FY2022 · HS
Vascular Function, Cognition, and Brain MRI in Atherosclerotic Vascular Disease
$469,862David J Moser · University Of Iowa · R01 · FY2010 · AG
Binding and regulation mechanism for S aureus
$469,854Ambrose L. Cheung · Dartmouth College · R01 · FY2006 · AI
MICROBIAL ISSUES OF FOOD SAFETY ARE AMONG THE MOST SIGNIFICANT CONSTRAINTS FOR RAW OR MINIMALLY PROCESSED PRODUCTS. THESE ISSUES RESULT DUE TO PRESENCE OF CONTAMINATING HUMAN PATHOGENS IN FRESH PRODUCE AND MEAT PRODUCTS AS WELL AS EMERGING CONCERNS WITH ANTIMICROBIAL RESISTANT BACTERIA IN FOOD PRODUCTS AND FOOD PROCESSING FACILITIES. TO OVERALL GOAL IS TO REDUCE THE RISK OF TRANSMISSION OF BOTH PATHOGENIC AND ANTIMICROBIAL RESISTANT BACTERIA THROUGH MINIMALLY PROCESSED FOOD AND TO MITIGATE PERSISTENCE OF ANTIMICROBIAL RESISTANT BACTERIA IN FOOD PROCESSING FACILITIES. TO ACHIEVE THIS GOAL, THE PROPOSED RESEARCH PLAN AIMS TO DEVELOP INNOVATIVE PARTICLE BASED SANITIZERS THAT CAN ACHIEVE REDUCTION OF 4-5 LOG CFU/G ON SURFACE OF MINIMALLY PROCESSED FOODS AND FOOD CONTACT SURFACES. THE CENTRAL HYPOTHESIS OF THE PROPOSED RESEARCH IS THAT PARTICLE BASED SANITIZERS PROVIDE A COMBINATION OF MECHANICAL SHEAR, LOCALIZED HIGH CONCENTRATION OF SANITIZERS AND HIGH AFFINITY OF PARTICLES TO BIND DIVERSE BACTERIA ON FOOD PRODUCTS AND FOOD CONTACT SURFACES. TO ACHIEVE THESE UNMET NEEDS, THE PROPOSED RESEARCH WILL DEVELOP BOTH ENGINEERED AND BIO-BASED PARTICLE SANITIZERS AND DEMONSTRATE THEIR EFFECTIVENESS TO ACHIEVE 4-5 LOG CFU/G REDUCTION IN PATHOGENIC AND ANTIMICROBIAL RESISTANT MICROBES ON FOOD SURFACES AND BIOFILMS ON FOOD CONTACT SURFACES. SUCCESS OF THIS PROJECT WILL SIGNIFICANTLY REDUCE THE RISK OF FOOD BORNE OUTBREAKS, AND ADDRESS THE UNMET NEED OF REDUCING PERSISTENCE AND TRANSMISSION OF ANTIMICROBIAL RESISTANCE MICROBES IN OUR FOOD SUPPLY CHAIN. THIS IMPACT WILL BE REALIZED BASED ON DEVELOPMENT AND COMMERCIALIZATION OF THESE INNOVATIVE TECHNOLOGIES.
$469,836University Of California, Davis · · FY2018 · National Institute of Food and Agriculture